Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829461 | 0.84 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL5829462 | 0.84 | SLC6A2 (0.52) | SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL5193526 | 0.82 | ALDH1A1 (0.52) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| SCHEMBL1424423 | 0.81 | GRIN2B (0.52) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| SCHEMBL1844989 | 0.81 | GRIN2B (0.52) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| SCHEMBL1424424 | 0.81 | GRIN2B (0.52) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL1773932 | 0.80 | DRD2 (0.51) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| Hydrochloric Acid SCHEMBL1773933 | 0.80 | DRD2 (0.51) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| SCHEMBL5194656 | 0.78 | SLC6A4 (0.74) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 | |
| SCHEMBL22646520 | 0.77 | OPRD1 (0.55) | SLC6A4SLC6A2SLC6A3GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2005-04-28 | — | — | US | disclosed |
| US-6867207-B2 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-15 | — | — | US | disclosed |
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | LACRAMPE JEAN FERNAND ARMAND (FR) | 2004-08-26 | — | — | US | disclosed |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | LACRAMPE JEAN FERNAND ARMAND (FR) | 2002-06-13 | — | — | US | disclosed |
| EP-1000040-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999002505-A1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167333-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | IL6ST, CXCR5, ALOX5 | SLC6A4 1457/4885SLC6A2 2588/4885SLC6A3 2028/4885 |
| US-20050090495-A1 | Novel IL-5 inhibiting 6-azauracil derivatives for marking and identifying receptors and imaging organs | CXCR5, HCAR3, IL6ST | SLC6A4 1687/4885SLC6A2 2600/4885SLC6A3 1138/4885 |
| US-20020072603-A1 | Novel IL-5 inhibiting 6-azauracil derivatives | IL6ST, ALOX5, IL5 | SLC6A4 2993/4885SLC6A2 3875/4885SLC6A3 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.